Treatment of Cavitary Tuberculosis

Initial Treatment Regimen

The American Thoracic Society recommends treating cavitary pulmonary tuberculosis with a standard 6-month regimen, consisting of 2 months of isoniazid, rifampin, pyrazinamide, and ethambutol, followed by 4 months of isoniazid and rifampin, but extending the continuation phase to 7 months if sputum culture remains positive at 2 months 1, 2, 3
The initial intensive phase requires four-drug therapy, including isoniazid 5 mg/kg daily, rifampin 10 mg/kg daily, pyrazinamide weight-based dosing, and ethambutol 15 mg/kg daily, to prevent resistance development 1, 2

At 2 months, obtain sputum culture to determine continuation phase duration, and if the culture is negative, continue isoniazid and rifampin for 4 additional months, but if the culture is positive, extend the continuation phase to 7 additional months 1, 2, 3
The Centers for Disease Control and Prevention recommends that patients with cavitary disease who demonstrate culture conversion at 2 months should continue isoniazid and rifampin for 4 additional months 1

Before initiating treatment, obtain three sputum specimens for AFB smear and culture with drug susceptibility testing, baseline chest radiograph, baseline liver function tests, serum creatinine, and platelet count, and perform visual acuity and red-green color discrimination testing for patients on ethambutol 5, 1, 2, 3
During treatment, perform monthly sputum cultures until two consecutive negative cultures are documented, and monthly clinical evaluation to assess adherence and adverse effects 5, 3

For HIV co-infection, use the same standard regimen but with critical modifications, including extending treatment to 9 months total if CD4 count is <100 cells/mm³, and using daily or three times weekly dosing, but never once-weekly rifapentine regimens 1, 5, 3
For renal impairment, avoid ethambutol and streptomycin if possible, and monitor serum drug concentrations and substantially reduce doses unless dialysis is used 6
For pre-existing liver disease, use all drugs with weekly liver function monitoring for the first 2 weeks, then every 2 weeks for the first 2 months, but stop rifampin, isoniazid, and pyrazinamide immediately if AST/ALT rises to 5 times normal or bilirubin rises 6, 7, 3

The continuation phase may be administered daily, twice weekly by directly observed therapy (DOT), or three times weekly by DOT, but never use once-weekly rifapentine regimens in cavitary TB or HIV-positive patients 1, 8

Never discontinue ethambutol before 2 months unless drug susceptibility results confirm no resistance, and never continue pyrazinamide beyond 2 months even when extending treatment to 9 months 1, 2, 4
Never add a single drug to a failing regimen, and never rely on clinical improvement alone, but instead use bacteriologic confirmation with negative cultures to determine cure 3, 2